244. Factor VIII Immunogenicity Is a Barrier to AAV Gene Therapy for Hemophilia A

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33849-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

AAV-mediated Gene Transfer for Hemophilia

Genetics in Medicine
MedicineGenetics
2002English

Postpartum Acquired Hemophilia Factor VIII �nhibitors and Response to Therapy

Turkish Journal of Haematology
Hematology
2012English

Immune Tolerance Induced by Platelet-Targeted Factor VIII Gene Therapy in Hemophilia a Mice Is CD4 T Cell-Mediated

Journal of Thrombosis and Haemostasis
MedicineHematology
2017English

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2012English

Lentivirus-Mediated Platelet Gene Therapy of Murine Hemophilia a With Pre-Existing Anti-Factor VIII Immunity

Journal of Thrombosis and Haemostasis
MedicineHematology
2012English

Creating a DDAVP Releasable Pool of Factor VIII: Its Impact on the Gene Therapy of Hemophilia a † 786

Pediatric Research
Child HealthPediatricsPerinatology
1998English

Role of the Vector Genome and Underlying Factor IX Mutation in Immune Responses to AAV Gene Therapy for Hemophilia B

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

Effect of Route of Administration of Human Recombinant Factor VIII on Its Immunogenicity in Hemophilia a Mice

Journal of Pharmaceutical Sciences
Pharmaceutical Science
2009English

HLA-DRB1–factor VIII Binding Is a Risk Factor for Inhibitor Development in Nonsevere Hemophilia: A Case-Control Study

Blood advances
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy